UPClytics
ENDE
Sign inStart trial
View all cases

UPC CFI 463/2024

Aug 30, 2024·EP2493466 · NOVEL ANTITUMORAL USE OF CABAZITAXEL

Follow
Case details
Status
Case Closed
Action
Counterclaim for revocation
Category
Counterclaim for revocation
Parties
Claimants
Representatives
Respondents
Representatives
Division
Munich LD
Judges
Technology
  • Chemistry
    Pharmaceuticals
Language
English
EPO Opposition
How this compares
The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.
Patent revokedMedian days to first decision
All UPC37% (34/91)124
Munich LDLockedLocked
Judge Matthias ZigannLockedLocked
Judge Alima ZanaLockedLocked
Judge Tobias PichlmaierLockedLocked

At the UPC: Accord Group (8 cases)·Sanofi Group (33 cases)

Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patent

This dispute contains 3 other proceedings

UPC CFI 145/2024·UPC APP 54972/2024·UPC APP 907/2025

13 other defendants litigating the same or a related patent

UPC CoA 22/2026·UPC CoA 23/2026·UPC CoA 24/2026·UPC CoA 25/2026·UPC CoA 26/2026 and 8 more

Start a free trial to see how each one ended.

More cases: Munich LD·2024

Documents
Document titleDatePublic
Case closed2025-11-27Not public
Other Documents2025-11-25Not public
Oral procedure closed2025-10-11Not public
Decision2025-10-11Not public
Final Order2025-10-11Public
Cover sheet2025-10-10Not public
Application2025-10-10Not public
Signature image2025-10-10Not public
Receipt2025-10-10Not public
Cover sheet2025-10-10Not public
Other document2025-10-10Not public
Receipt2025-10-10Not public
Cover sheet2025-10-08Not public
Further pleadings2025-10-08Not public
Exhibit2025-10-08Not public
Receipt2025-10-08Not public
Cover sheet2025-10-08Not public
Further pleadings2025-10-08Not public
Exhibit2025-10-08Not public
Receipt2025-10-08Not public
oral hearing reference - IC2025-09-15Not public
oral hearing reference - IC2025-09-15Not public
Fix-Interim-Conference-Date2025-09-10Not public
Interim-Conference-Decision2025-09-10Not public
Written-Procedure-Closure2025-09-10Not public
Acknowledgement-of-lodging2025-08-08Not public
Exhibit No. B.2.2.12025-08-08Not public
Exhibit No. B.22.1bis2025-08-08Not public
Exhibit No. B.342025-08-08Not public
Exhibit No. B.372025-08-08Not public
Exhibit No. B.312025-08-08Not public
Exhibit No. B.432025-08-08Not public
Exhibit No. 0.52025-08-08Not public
Exhibit No. B.2.2.22025-08-08Not public
Exhibit No. B.322025-08-08Not public
Exhibit No. B.302025-08-08Not public
Exhibit No. B.412025-08-08Not public
Exhibit No. B.362025-08-08Not public
Exhibit No. B.382025-08-08Not public
Exhibit No. B.352025-08-08Not public
Exhibit No. B.392025-08-08Not public
Rejoinder2025-08-08Not public
Exhibit No. B.422025-08-08Not public
Exhibit No. B.332025-08-08Not public
Exhibit No. B.402025-08-08Not public
Outcome of the Order2025-07-16Not public
262 A - final (again for the old CMS)2025-07-16Public
262 A - final2025-07-16Public
Acknowledgement-of-change-of-a-representative2025-07-11Not public
ACT_16112-2024 and 4499-2024 Accord Application 262A RoP 8 July 2025.pdf2025-07-09Not public
ACT_16112-2024 and 4499-2024 Accord Reply to the Defence to the Counterclaim and Rejoinder UNREDACTED version 8 July 2022025-07-09Not public
ACT_16112-2024 and 4499-2024 Accord Reply to the Defence to the Counterclaim and Rejoinder REDACTED version 8 July 2025.2025-07-09Not public
Acknowledgement-of-lodging2025-07-09Not public
Exhibit TW 8.16 Accord s Comments on Sanofi s further amended requests - filed 9 April 2025.pdf2025-07-09Not public
Exhibit TW 6.3 - Paris Court Judgment issued on 6 September 2024 Accord v Sanofi RG 21-06416.pdf2025-07-09Not public
Exhibit TW 8.2 UPC_CFI_145-2024 (LD Munich) order of 5 November 2024.pdf2025-07-09Not public
Exhibit TW 8.10 UPC_CFI_148-2024 (LD Munich) Order of 27 June 2025.pdf2025-07-09Not public
Exhibit TW 8.12 Accord s Rejoinder to the Sanofi s comments on the Preliminary Objections - filed 11 October 2024.pdf2025-07-09Not public
Exhibit TW 8.11 Accord s Preliminary Objections and Generic Procedural Application - filed 1 July 2024.pdf2025-07-09Not public
Exhibit TW 6.5 Schedule of costs for the Defendants as of 8 July 2025 (signed).pdf2025-07-09Not public
Exhibit TW 8.8 UPC_CFI_145-2024 (LD Munich) Order of 27 February 2025.pdf2025-07-09Not public
Exhibit TW 6.4 Sanofi Winthrop Industries annuals report for the period 2020 2025.pdf2025-07-09Not public
Exhibit TW 6.4 Sanofi Winthrop Industries annuals report for the period 2020 2025.pdf2025-07-09Not public
Exhibit TW 8.1 UPC_CFI_145-2024 (LD Munich) orders of 1st October 2024.pdf2025-07-09Not public
Exhibit TW 5.35bis Sanofi Annual Report 20-F 2008 in the US (complete version).pdf2025-07-09Not public
Exhibit TW 8.4 UPC_CFI_145-2024 (LD Munich) order of 3 January 2025.pdf2025-07-09Not public
Exhibit TW 8.13 Accord Comments on 262A Sanofi s request - filed on 12 November 2024.pdf2025-07-09Not public
Exhibit TW 8.7 UPC_CFI_145-2024 (LD Munich) order of 22 January 2025.pdf2025-07-09Not public
Exhibit TW 8.15 Official communication 3 March 2025 from Accord UPC representatives to Sanofi UPC representatives.pdf2025-07-09Not public
Exhibit TW 8.9 UPC_CFI_145-2024 (LD Munich) Order of 8 May 2025 REDACTED version.pdf2025-07-09Not public
Exhibit TW 7.2 Extracts W Tilmann and C Plasmann Unified Patent Protection in Europe A Commentary book 1st Ed published2025-07-09Not public
Exhibit TW 8.3 UPC_CFI_145-2024 (LD Munich) order of 19 December 2024.pdf2025-07-09Not public
Exhibit TW 8.5 UPC_CFI_145-2024 (LD Munich) order of 9 January 2025.pdf2025-07-09Not public
Exhibit TW 8.6 UPC_CFI_145-2024 (LD Munich) order of 14 January 2025.pdf2025-07-09Not public
ACT_16112-2024 and 4499-2024 Accord Reply to the Defence to the Counterclaim and Rejoinder UNREDACTED version 8 July 2022025-07-09Not public
ACT_16112-2024 and 4499-2024 Accord Reply to the Defence to the Counterclaim and Rejoinder UNREDACTED version 8 July 2022025-07-09Not public
Exhibit TW 8.14 Accord Comments on Sanofi amended requests and Rejoinder to Sanofi comments - filed on 12 February 2025.2025-07-09Not public
Exhibit TW 6.3 - Paris Court Judgment issued on 6 September 2024 Accord v Sanofi RG 21-06416.pdf2025-07-09Not public
Application-RoP293-Receipt2025-07-08Not public
Formal-checks_Notification-of-positive-outcome2025-07-08Not public
Application-RoP2932025-06-27Not public
Application2025-06-27Not public
Acknowledgement-of-change-of-a-representative2025-05-23Not public
Acknowledgement-of-change-of-a-representative2025-05-23Not public
Acknowledgement-of-change-of-a-representative2025-05-23Not public
Acknowledgement-of-change-of-a-representative2025-05-23Not public
Acknowledgement-of-change-of-a-representative2025-05-23Not public
Acknowledgement-of-change-of-a-representative2025-05-23Not public
Acknowledgement-of-change-of-a-representative2025-05-23Not public
Acknowledgement-of-change-of-a-representative2025-05-22Not public
Application-RoP293-Receipt2025-05-22Not public
Formal-checks_Notification-of-positive-outcome2025-05-22Not public
Application-RoP293-Receipt2025-05-22Not public
Formal-checks_Notification-of-positive-outcome2025-05-22Not public
Application-RoP293-Receipt2025-05-22Not public
Formal-checks_Notification-of-positive-outcome2025-05-22Not public
Application-RoP293-Receipt2025-05-22Not public
Formal-checks_Notification-of-positive-outcome2025-05-22Not public
Application-RoP293-Receipt2025-05-22Not public
Formal-checks_Notification-of-positive-outcome2025-05-22Not public
Application-RoP293-Receipt2025-05-22Not public
Formal-checks_Notification-of-positive-outcome2025-05-22Not public
Application-RoP293-Receipt2025-05-22Not public
Formal-checks_Notification-of-positive-outcome2025-05-22Not public
Application-RoP2932025-05-22Not public
Application - Change of Representative - Jules Fabre Signed 20250519.pdf2025-05-22Not public
Application-RoP2932025-05-22Not public
Application - Change of Representative - Jules Fabre Signed 20250519.pdf2025-05-22Not public
Application-RoP2932025-05-22Not public
Application - Change of Representative - Jules Fabre Signed 20250519.pdf2025-05-22Not public
Application-RoP2932025-05-22Not public
Application - Change of Representative - Jules Fabre Signed 20250519.pdf2025-05-22Not public
Application-RoP2932025-05-22Not public
Application - Change of Representative - Jules Fabre Signed 20250519.pdf2025-05-22Not public
Application-RoP2932025-05-22Not public
Application - Change of Representative - Jules Fabre Signed 20250519.pdf2025-05-22Not public
Application-RoP2932025-05-22Not public
Application - Change of Representative - Jules Fabre Signed 20250519.pdf2025-05-22Not public
Application-RoP293-Receipt2025-05-21Not public
Formal-checks_Notification-of-positive-outcome2025-05-21Not public
Application-RoP2932025-05-19Not public
Application Change of Representative2025-05-19Not public
Hearing-Dates2025-01-24Not public
scheduling IC and OH for CC2025-01-24Public
Hearing-Dates2025-01-24Not public
Outcome of the Order2025-01-17Not public
R 305 second - final2025-01-17Public
Hearing Reference2025-01-16Not public
Hearing Reference2025-01-16Not public
Hearing-Dates2025-01-13Not public
R 305 second- oral comments2025-01-13Not public
Receipt2025-01-09Not public
Application2025-01-09Not public
Exhibit No. A.02.22025-01-09Not public
Outcome of the Order2024-12-19Not public
extension request2024-12-19Public
Receipt2024-12-10Not public
2024 12 09 - Accord - Request for extension of deadline2024-12-09Not public
Acknowledgement-of-lodging2024-12-05Not public
2024 12 05 - Application to change details of a representative 64597- 20242024-12-05Not public
Formal-checks_Notification-of-positive-outcome2024-11-01Not public
Acknowledgement-of-lodging2024-11-01Not public
Reply and Defence2024-11-01Not public
epoUploadDocumentsWorkflow2024-09-17Not public
Document from EPO2024-09-16Not public
Acknowledgement of access to case2024-09-06Not public
Notification Of Service2024-09-06Not public
Panel-Appointment2024-09-06Not public
EPO-Request-for-case-pending2024-09-06Not public
Acknowledgement-of-lodging2024-09-06Not public
Formal-checks_Notification-of-positive-outcome2024-09-04Not public
Exhibit PM 5.23 Wayback machine extracts from ClinicalTrial.gov. 2008 and 20092024-08-30Not public
Exhibit PM 2.7 Revue Prescrire Cabazitaxel Jevtana Trop toxique pour une efficacite trop incertaine October 20112024-08-30Not public
Exhibit PM 2.5 Refusal notice issued by the INESSS in February 20152024-08-30Not public
Exhibit PM 5.30 Screenshot from OpenPaymentsData.CMS.gov2024-08-30Not public
Exhibit PM 5.20 Beardsley et al. Systemic therapy after first-line docetaxel (...) 20082024-08-30Not public
Exhibit PM 2.4 Le Monde Sanofi Londres refuse de rembourser le Jevtana of 13 January 20122024-08-30Not public
Exhibit PM 2.1 Summary of product characteristics of Jevtana2024-08-30Not public
Exhibit PM 2.7 Revue Prescrire Cabazitaxel Jevtana Trop toxique pour une efficacite trop incertaine October 20112024-08-30Not public
Exhibit PM 6.1 Excerpts IQVIA Audit Data Presentation July 20242024-08-30Not public
Exhibit PM 5.26 Correspondence in The Lancet (2011) re PM 5.25 Froehner and Wirth v. De Bono2024-08-30Not public
Exhibit PM 1.1 French company registry extract for Sanofi Mature IP2024-08-30Not public
Exhibit PM 2.6 Opinion of the Transparency Committee of the French National Health Authority 17 October 20122024-08-30Not public
Exhibit PM 5.16 Oudard et al. Multicenter randomized phase II study (...) May 20052024-08-30Not public
Exhibit PM 1.3 Communication from the Paris Court of First Instance dated 5 July 20242024-08-30Not public
Exhibit PM 4.11 Notice of appeal Accord of 15 January 20242024-08-30Not public
Exhibit PM 5.33 Extracts from Sanofi Annual Report 20082024-08-30Not public
Exhibit PM 5.5 US 2005 065138 A12024-08-30Not public
Exhibit PM 5.2 Annexes to the declaration by Dr Samuel Denmaede (part 3)2024-08-30Not public
Exhibit PM 4.7 Record of the assignment of EP 466 during its examination before the EPO2024-08-30Not public
Exhibit PM 5.19 Pivot et al. A multicenter phase II study of XRP6258 (...) 20082024-08-30Not public
Exhibit PM 5.3 Declaration by Dr. Kurt Miller2024-08-30Not public
44999-2024 proof of Court fees payment2024-08-30Not public
Exhibit PM 4.12 Grounds of appeal Accord of 24 May 20242024-08-30Not public
Exhibit PM 5.9 ICH Topic E8 Note for guidance on general considerations for clinical trials March 19982024-08-30Not public
Exhibit PM 5.2 Annexes to the declaration by Dr Samuel Denmaede (part 4)2024-08-30Not public
Exhibit PM 5.2 Annexes to the declaration by Dr. Samuel Denmaede (part 1)2024-08-30Not public
Exhibit PM 4.8 Notice of opposition Accord of 10 March 20212024-08-30Not public
Exhibit PM 5.15 Petrylak et al. Docetaxel and estramustine compared (...) 2004 Oct.2024-08-30Not public
Exhibit PM 5.28 Declaration by Dr. Sartor before the Patent and trial and appeal board 20 April 20172024-08-30Not public
Exhibit PM 5.7 Tannock et al. Docetaxel plus prednisone or mitoxantrone plus prednisone (...) 2004 Oct.2024-08-30Not public
Exhibit PM 1.1 French company registry extract for Sanofi Mature IP2024-08-30Not public
Exhibit PM 5.35 Extracts Sanofi Annual report 20-F 2008 in the US2024-08-30Not public
Exhibit PM 5.10 CHMP guideline on the evaluation of anticancer medicinal products in man December 20052024-08-30Not public
Exhibit PM 5.2 Annexes to the declaration by Dr. Samuel Denmaede (part 2)2024-08-30Not public
Exhibit PM 5.29 Extracts from Dr. Sartor deposition transcript of 8 May 2017 in the US proceedings2024-08-30Not public
Exhibit PM 2.4 Le Monde Sanofi Londres refuse de rembourser le Jevtana of 13 January 20122024-08-30Not public
Exhibit PM 2.3 Opinion of the Transparency Committee of the French National Health Authority of 19 October 20112024-08-30Not public
Exhibit PM 5.32 Madan et al. Overcoming Chemotherapy Resistance in Prostate Cancer (...) June 20112024-08-30Not public
Exhibit PM 4.2 WO 2011 051894 A12024-08-30Not public
Exhibit PM 5.6 Extracts from the Summary of Product Characteristics of Taxotere2024-08-30Not public
Exhibit PM 5.36 Galletti et al. Paclitaxel and Docetaxel Resistance (...) 20072024-08-30Not public
Exhibit PM 1.2 Extract Sanofi annual reports2024-08-30Not public
Exhibit PM 5.4 Declaration by Prof. Stefan Muller2024-08-30Not public
Exhibit PM 4.10 Opposition Division reasoned decision dated on 25 January 20242024-08-30Not public
Exhibit PM 1.3 Communication from the Paris Court of First Instance dated 5 July 20242024-08-30Not public
Exhibit PM 5.24 Screenshot from ClinicalTrial.gov XRP6258 Plus Prednisone Compared to (...) 3 May 20212024-08-30Not public
Exhibit PM 5.25 De Bono et al. Prednisone plus cabazitaxel or mitoxantrone (...) The Lancet 20102024-08-30Not public
Exhibit PM 5.13 Scher et al. Design and end points of clinical trials for patients (...) 20082024-08-30Not public
Exhibit PM 5.22 Sanofi press release dated 21 December 20092024-08-30Not public
Exhibit PM 5.21 TROPIC trial protocol in a document entitled Cabazitaxel (XRP-6258) for hormone (...) 20092024-08-30Not public
Exhibit PM 2.2 Neutropenia MSD Manual2024-08-30Not public
Exhibit PM 5.18 Mita et al. Phase I and pharmacokinetic study of XRP6258 (...) 20092024-08-30Not public
ACT_16112-2024 and 4499-2024_Accord_Statement of Defence and Counterclaim for Revocation_30 August 20242024-08-30Not public
Exhibit PM 5.8 Tannock et al. Chemotherapy with mitoxantrone plus prednisone (...)1996 Jun.2024-08-30Not public
Exhibit PM 4.5 Extracts from the European Patent register for EP 2 493 466 as at 21 August 20242024-08-30Not public
Exhibit PM 5.14 Label Novantrone (Mitoxantrone) FDA2024-08-30Not public
Exhibit PM 3.1 Summary of product characteristics of Cabazitaxel Accord2024-08-30Not public
Exhibit PM 4.6 Summons to oral proceedings by the Board of Appeal and date confirmation2024-08-30Not public
Exhibit PM 5.12 Declaration of Helsinki Ethical Principles of Medical Research involving Human Subjects October 20082024-08-30Not public
Exhibit PM 6.2 Order 7 June 2022 First Instance Court2024-08-30Not public
Exhibit PM 7.1 Extract Paul England A practioners Guide to the UPC and UP Dec 20222024-08-30Not public
Exhibit PM 5.11 Wong and Siah Estimation of clinical trial success rates and related parameters Biostatistics 20192024-08-30Not public
Exhibit PM 5.17 Berthold et al. Survival and PSA response of patients in the TAX 327 study2024-08-30Not public
Exhibit PM 5.34 Fitzpatrick et al. Treatment Decisions for Advanced Genitourinary (...) 20092024-08-30Not public
Exhibit PM 5.31 Kumar Pal et al. Critical appraisal of cabazitaxel (...) Clinical Interventions in Aging 20102024-08-30Not public
Exhibit PM 4.13 Decision of the United States Patent Office (USPTO) of 22 October 20192024-08-30Not public
Exhibit PM 2.5 Refusal notice issued by the INESSS in February 20152024-08-30Not public
Exhibit PM 4.3 Priority document No. US 61 256 160 (P1)2024-08-30Not public
Exhibit PM 4.14 IP.appify Blog of 12 janvier 2024 Caselaw-EPO-reviews of EPO BoA decisions of D.X. Thomas2024-08-30Not public
Exhibit PM 4.1 EP E 493 466 B12024-08-30Not public
Exhibit PM 2.8 Sales of Jevtana in European countries in 2020 (based on IQVIA data)2024-08-30Not public
Exhibit PM 4.4 Priority document No. US 61 293 903 (P2)2024-08-30Not public
Exhibit PM 5.1 Declaration by Dr. Samuel Denmeade2024-08-30Not public
Exhibit PM 5.27 Declaration by Dr. Sartor of 23 December 20202024-08-30Not public
Exhibit PM 4.9 Further observations Accord of 10 December 20212024-08-30Not public
Exhibit PM 6.2 Order 7 June 2022 First Instance Court2024-08-30Not public